A 5th Circuit panel reversed a district court stay and ordered nationwide in-person-only mifepristone dispensing, triggering emergency Supreme Court intervention in May 2026.
A three-judge panel of the U.S. Court of Appeals for the 5th Circuit, composed entirely of Republican appointees, reversed a district court's stay of its own ruling and issued an order requiring that mifepristone be dispensed in person only, effective immediately and nationwide [1]. The order did not confine its reach to Louisiana, the state whose challenge gave rise to the litigation. Danco Laboratories, a manufacturer of mifepristone, characterized the order as unprecedented, arguing that no federal court had previously moved to immediately enjoin a years-old FDA drug approval [1]. The ruling eliminated, for the duration of its effect, telehealth prescriptions and mail dispensing of the drug across all 50 states.
The case, Louisiana v. FDA, was brought by the State of Louisiana challenging federal rules permitting mifepristone to be prescribed remotely and dispensed through certified pharmacies and mail [2]. The 5th Circuit panel's action came on appeal from a district court that had entered a ruling favorable to Louisiana but then stayed that ruling pending further proceedings [1]. The panel reversed the stay, triggering the order's immediate effect. The case is proceeding before the New Orleans-based court, whose jurisdiction covers Louisiana, Mississippi, and Texas, though the injunction the panel issued carried nationwide scope.
The ruling's significance extends well beyond mifepristone access. By issuing an injunction that reached every state, including those where abortion remains legal and where state law expressly permits telehealth prescriptions for the drug, the panel placed 5th Circuit authority in direct tension with the regulatory posture of the FDA and with the legal regimes of dozens of states [2]. The nationwide scope is what elevated the dispute into an immediate emergency at the Supreme Court level. Critics of the order argued that a regional appellate panel lacks a sound doctrinal basis for imposing a uniform dispensing requirement on states whose own laws conflict with it [1].
The Supreme Court responded by briefly extending telehealth and mail access for mifepristone while it considered emergency applications filed by Danco Laboratories and other parties [1]. That interim relief preserved the pre-order status quo on a temporary basis. The Court's ultimate disposition of the emergency applications, and its potential consideration of the merits, is expected to produce a ruling with significant consequences for FDA rulemaking authority and for the federal-state allocation of power over drug access in the post-Dobbs landscape [2]. Briefing on the emergency applications was proceeding as of early May 2026.